Polysialic acids: potential in improving the stability and pharmacokinetics of proteins and other therapeutics

Abstract. Naturally occurring polymers of N-acetylneuraminic acid (polysialic acids) are biodegradable, highly hydrophilic and have no known receptors in the body. Following intravenous injection, polysialic acids exhibit long half-lives in the blood circulation and have therefore been proposed as carriers of short-lived drugs and small peptides. In addition, shorter-chain polysialic acids can be used as a means to increase the circulatory half-life of proteins and thus serve as an alternative to the nonbiodegradable monomethoxypoly(ethylene glycol). Recent work has shown that covalent coupling of a low molecular weight polysialic acid (colominic acid) to catalase and asparaginase leads to a considerable increase of enzyme stability in the presence of proteolytic enzymes or blood plasma. Comparative studies in vivo with polysialylated and intact asparaginase revealed that polysialylation significantly increases the half-life of the enzyme. The highly hydrophilic and innocuous nature of polysialic acids renders them suitable as a means to prolong the circulation of peptides and proteins.

[1]  C Delgado,et al.  The uses and properties of PEG-linked proteins. , 1992, Critical reviews in therapeutic drug carrier systems.

[2]  O. Nishimura,et al.  Lipid on capsular polysaccharides of gram-negative bacteria. , 1981, The Journal of biological chemistry.

[3]  M. Papisov,et al.  Why do Polyethylene Glycol-Coated Liposomes Circulate So Long?: Molecular Mechanism of Liposome Steric Protection with Polyethylene Glycol: Role of Polymer Chain Flexibility , 1994 .

[4]  F. Kuypers,et al.  Erythrocyte defense against hydrogen peroxide: preeminent importance of catalase. , 1991, The Journal of laboratory and clinical medicine.

[5]  J. Uren,et al.  Improvement in the therapeutic, immunological, and clearance properties of Escherichia coli and Erwinia carotovora L-asparaginases by attachment of poly-DL-alanyl peptides. , 1979, Cancer research.

[6]  M. Laguerre,et al.  Erythrocytes as Carriers for L‐Asparaginase. Methodological and Mouse In‐vivo Studies , 1990, The Journal of pharmacy and pharmacology.

[7]  G. Gregoriadis,et al.  Polysialic acids: potential in drug delivery , 1993, FEBS letters.

[8]  C. Wiblin,et al.  The effect of chemical modification of L-asparaginase on its persistence in circulating blood of animals. , 1979, Biochemical pharmacology.

[9]  J. Finne Occurrence of unique polysialosyl carbohydrate units in glycoproteins of developing brain. , 1982, The Journal of biological chemistry.

[10]  L. Pelliniemi,et al.  The Polysialic Acid Units of the Neural Cell Adhesion Molecule N-CAM Form Filament Bundle Networks* , 1998, The Journal of Biological Chemistry.

[11]  V. Bocci Metabolism of protein anticancer agents. , 1987, Pharmacology & therapeutics.

[12]  M. Keating,et al.  L-asparaginase and PEG asparaginase--past, present, and future. , 1993, Leukemia & lymphoma.

[13]  M. Nucci,et al.  The therapeutic value of poly(ethylene glycol)-modified proteins , 1991 .

[14]  G. Gregoriadis,et al.  Polysialylated asparaginase: preparation, activity and pharmacokinetics. , 1997, Biochimica et biophysica acta.

[15]  R. Mandrell,et al.  Measurement of antibodies to meningococcal group B polysaccharide: low avidity binding and equilibrium binding constants. , 1982, Journal of immunology.

[16]  M. Lifely,et al.  Immunity and protection of mice against Neisseria meningitidis group B by vaccination, using polysaccharide complexed with outer membrane proteins: a comparison with purified B polysaccharide , 1985, Infection and immunity.

[17]  G. Gregoriadis,et al.  Synthesis, characterization and properties of sialylated catalase. , 1996, Biochimica et biophysica acta.

[18]  G. Gregoriadis,et al.  Tumour regression with liposome-entrapped asparaginase: some immunological advantages. , 1976, Biochemical Society transactions.